CAPE Patient Engagement & Implementation Evaluation Pilot Study
Thank you for your interest in participating in the CAPE Patient Engagement & Implementation Evaluation Pilot Study supported by the following principal investigators: Academy of Oncology Nurse & Patient Navigators (AONN+) and The Research Institute of Fox Chase Cancer Center.
The following Letter of Intent outlines an overview of the study, requirements of participant sites, and information to be submitted.
When diagnosed with cancer, a patient and their family’s quality of life (QOL) is often impacted immediately. QOL includes physical, psychological, social, and spiritual aspects of a patient. Responses such as anxiety and fear after the initial phase of cancer diagnosis and treatment are predominant and can lead to a multitude of barriers exclusively related to QOL. QOL ultimately affects most aspects of a patient’s cancer-care experience, specifically comprehension, coping, and self-care decisions. To address QOL with high-quality care, it is essential to have extensive patient education covering the entire disease trajectory.
- With the help of an integrated educational program (CAPE) for newly diagnosed patients who are between their cancer diagnosis and the start of first treatment, there is an opportunity to actively engage patients and caregivers by assigning them tasks relevant to their diagnosis, increase productivity, and allow patients to become more involved in their treatment decisions and trajectory, ultimately increasing their QOL. The impact of the CAPE program to facilitate shared decision-making and improve patient satisfaction and reduce anxiety are also impactful to QOL and will be explored with the utilization of this program.
This multisite evaluation study will employ a mixed-methods approach using both qualitative and quantitative data to explore the perceptions and utilization of this comprehensive patient education platform on newly diagnosed non–small-cell lung cancer (NSCLC) patients, provider attitudes toward the platform and genomic testing, and implementation of the tool in diverse clinical settings. These insights and findings will guide future efforts to introduce the CAPE platform in a broad array of oncology care.
Applicants must complete and submit this Letter of Intent (LOI) by 5:00 pm EST on Monday, December 14, 2020.
Institutions that submit a timely, completed LOI will then be redirected to a webpage where they can submit an electronic application. Only those institutions submitting a timely, completed LOI will be eligible to submit an application. Applications must be received by 5:00 pm EST on Monday, December 21, 2020.
LOI Submission Form
The deadline for the LOI submission has passed.